You can add items from the left menu by dragging them here.
NOLVADEX (tamoxifen citrate) is a nonsteroidal agent which has demonstrated potent antiestrogenic
properties in animal test systems. The antiestrogenic effects
might be related
to its capability to compete with estrogen for binding sites in target tissues
like breast. Tamoxifen inhibits
the induction of rat mammary carcinoma induced
by dimethylbenzanthracene (DMBA) to cause the regression of already established
DMBA-induced tumors. In
this particular rat model, tamoxifen appears to be exert its antitumor
effects by binding the estrogen receptors.
In cytosols
produced by human breast adenocarcinomas, tamoxifen competes with
estradiol for estrogen receptor protein.
Absorption and Distribution
Following 1 oral
dose of 20 mg tamoxifen, a normal peak plasma concentration
of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately
5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic that has a terminal
elimination half-life approximately
5 to 7 days. The typical peak plasma concentration
of N-desmethyl tamoxifen is 15 ng/mL (range 10 to 20 ng/mL).
Chronic administration
of 10 mg tamoxifen given two tmes a day for Three months to patients ends up with average/>steady-state plasma concentrations of 120 ng/mL (range 67-183 ng/mL) for tamoxifen
and 336 ng/mL (range 148-654 ng/mL) for N-desmethyl tamoxifen.
The common steady-state
plasma concentrations of tamoxifen and N-desmethyl tamoxifen after administration
of 20 mg tamoxifen once daily for 3
months are 122 ng/mL (range 71-183 ng/mL)
and 353 ng/mL (range 152-706 ng/mL), respectively. After initiation of therapy,
steady state
concentrations for tamoxifen are achieved inside Four weeks and
steady-state concentrations for N-desmethyl tamoxifen are achieved in approximately
Two months,
suggesting a half-life of around 14 days with this metabolite. In a steady-state, crossover study of 10 mg NOLVADEX (tamoxifen
citrate) tablets given 2 times a day
vs. a 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, the 20
mg NOLVADEX (tamoxifen citrate) tablet was
bioequivalent for the 10 mg NOLVADEX (tamoxifen citrate) tablets.
Metabolism
Tamoxifen is extensively
metabolized after oral administration. N-desmethyl
tamoxifen could be the major metabolite present in patients' plasma. The biological
activity of N-desmethyl
tamoxifen looks like it's just like that surrounding tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen
are
actually defined as minor metabolites in plasma. Tamoxifen is really a substrate
of cytochrome P-450 3A, 2C9 and 2D6, and
an inhibitor of P-glycoprotein.
Excretion
Studies in females receiving 20 mg of 14C tamoxifen demonstrate that
approximately 65% with
the administered dose was excreted through the body on the
quantity of Fourteen days with fecal excretion as being the
primary route of elimination. Its excreted mainly as polar conjugates, with unchanged drug and unconjugated
metabolites comprising a lot less
than 30% in the total fecal radioactivity.
Special Populations
The effects of age, gender and race on the pharmacokinetics
of tamoxifen have
not been determined. The results of reduced liver function about the metabolism
and pharmacokinetics of tamoxifen have
not been determined.
Pediatric Patients
The pharmacokinetics of tamoxifen and N-desmethyl tamoxifen were characterized
by using a population pharmacokinetic
analysis with sparse samples per patient
extracted from 27 female pediatric patients aged 2 to A decade signed up for
a
study made to assess the safety, efficacy, and pharmacokinetics of NOLVADEX (tamoxifen citrate)
for treating McCune-Albright Syndrome. Rich data
from two tamoxifen citrate pharmacokinetic
trials through which 59 postmenopausal women with cancer of the breast completed the studies
were
within the analysis to ascertain the structural pharmacokinetic model
for tamoxifen. A one-compartment model provided the most effective fit on
the data.
In pediatric patients, the normal steady state peak plasma concentration (Css,
max) and AUC were of 187
ng/mL and 4110 ng hr/mL, respectively, and Css, max
occurred approximately 8 hours after dosing. Clearance (CL/F) as body mass/>adjusted in female pediatric patients was approximately 2. 3-fold more than
in female cancer of the breast patients. In the
youngest cohort of female pediatric
patients (2-6 year olds), CL/F was 2. 6-fold higher; from the oldest cohort (7-10. 9/>year olds) CL/F was approximately 1. 9-fold higher. Contact N-desmethyl tamoxifen
was comparable involving the pediatric and adult patients. The
security and efficacy
of NOLVADEX (tamoxifen citrate) for girls aged two to Ten years with McCune-Albright Syndrome and
precocious puberty
haven't been studied beyond one full year of treatment. The long-term
results of NOLVADEX (tamoxifen citrate) therapy in girls haven't
been established. In older adults
cured with NOLVADEX (tamoxifen citrate) an boost in incidence of uterine malignancies, stroke
and pulmonary
embolism is noted (see BOXED WARNING).
Drug-Drug Interactions
In vitro studies revealed that erythromycin, cyclosporin, nifedipine and
diltiazem competitively
inhibited formation of N-desmethyl tamoxifen with apparent
K1 of 20, 1, 45 and 30 M, respectively. The clinical significance
these
in vitro studies is unknown.
Tamoxifen reduced the plasma power of letrozole by 37% when these drugs
were co-administered.
Rifampin, a cytochrome P-450 3A4 inducer reduced tamoxifen
AUC and Cmax by 86% and 55%, respectively. Aminoglutethimide reduces tamoxifen
and
N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces
plasma concentrations of N-desmethyl, but not tamoxifen.
In the anastrozole adjuvant trial, co-administration
of anastrozole and NOLVADEX (tamoxifen citrate)
in cancer of the breast patients reduced anastrozole plasma concentration by 27% compared
to
people achieved with anastrozole alone; however, the coadministration did
not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen (see PRECAUTIONS
-DRUG
INTERACTIONS). NOLVADEX (tamoxifen citrate) should cease
co-administered with anastrozole.
Studies
Metastatic Breast Cancer
Premenopausal Women (NOLVADEX (tamoxifen citrate) vs.
Ablation)
Three prospective, randomized studies (Ingle, Pritchard, Buchanan) compared
NOLVADEX (tamoxifen citrate) to ovarian ablation (oophorectomy or ovarian irradiation) in
premenopausal
women with advanced breast cancer. Although objective response rate, time
to treatment failure, and survival were similar with both
treatments, the limited
patient accrual prevented a demonstration of equivalence. In an overview analysis
of survival data from many studies,
the hazard ratio for death (NOLVADEX (tamoxifen citrate) /ovarian
ablation) was 1. 00 with two-sided 95% confidence intervals of 0.
73 one. 37. Elevated serum and plasma estrogens have been affecting premenopausal women
receiving NOLVADEX (tamoxifen citrate) , however the
data in the randomized studies don't suggest
an adverse effect of this increase. A limited quantity of premenopausal patients
with
disease progression during NOLVADEX (tamoxifen citrate) therapy responded to subsequent ovarian
ablation.
Male Cancers of the breast
Published results
from 122 patients (119 evaluable) and case reports in 16
patients (13 evaluable) addressed with NOLVADEX (tamoxifen citrate) have shown
that NOLVADEX (tamoxifen citrate) works well
for that palliative treating male breast cancers. Sixty-six of the 132 evaluable
patients responded
to NOLVADEX (tamoxifen citrate) which constitutes a 50% objective response rate.
Adjuvant Breast cancers
Overview
The Early Breast cancers
Trialists' Collaborative Group (EBCTCG) conducted worldwide
overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990,
and again
in 1995. In 1998, 10-year outcome data were reported for 36,689 women
in 55 randomized trials of adjuvant NOLVADEX (tamoxifen
citrate) using doses of 20-40 mg/day for
1-5+ years. Twenty-five percent of patients received A year or diminished amount of
trial
treatment, 52% received Two years, and 23% received about Several years. Forty-eight
percent of tumors were estrogen receptor (ER)
positive ( > 10 fmol/mg), 21%
were ER poor ( < 10 fmol/l), and 31% were ER unknown. Among 29,441
patients
with ER positive or unknown breast cancer, 58% were entered into trials comparing
NOLVADEX (tamoxifen citrate) to no adjuvant
therapy and 42% were entered into trials comparing NOLVADEX (tamoxifen citrate)
in combination with chemotherapy vs. the same chemotherapy alone.
Among these
patients, 54% had node positive disease and 46% had node negative disease.
Among women with ER positive
or unknown cancers of the breast and positive nodes who
received about 5yrs of treatment, overall survival at Several years
was 61. 4%
for NOLVADEX (tamoxifen citrate) vs. 50. 5% for control (logrank 2p < 0. 00001). The recurrence-free
rate
at 10 years was 59. 7% for NOLVADEX (tamoxifen citrate) vs. 44. 5% for control (logrank 2p <
0. 00001).
Among women with ER positive or unknown breast cancer and negative
nodes who received about 5 years of treatment, overall
survival at 10 years
was 78. 9% for NOLVADEX (tamoxifen citrate) vs. 73. 3% for control (logrank 2p < 0.
00001). The
recurrence-free rate at 10 years was 79. 2% for NOLVADEX (tamoxifen citrate) versus 64. 3% for control
(logrank
2p < 0. 00001).
The effect in the scheduled use of tamoxifen could be described as follows. Ladies with
ER positive or unknown breast cancer receiving A year or less,
Two years or about 5 years of NOLVADEX (tamoxifen
citrate) , the proportional reductions in mortality
were 12%, 17% and 26%, respectively (trend significant at 2p < 0. 003).
The
corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend
significant at 2p < 0. 00001).
/>
Benefit is less clear for female with ER poor cancer of the breast in whom the proportional
reduction in recurrence
was 10% (2p = 0. 007) for many durations taken together,
or 9% (2p = 0. 02) if contralateral breast
cancers are excluded. The attached
cut in mortality was 6% (NS). The end results of about 5yrs of NOLVADEX (tamoxifen
citrate)
on recurrence and mortality were similar irrespective of age and concurrent chemotherapy. There was no indication that doses more
than 20 mg each day were more efficient.
Anastrozole Adjuvant ATAC Trial - Study of Anastrozole when compared with
NOLVADEX (tamoxifen citrate)
for Adjuvant Management of Early Cancer of the breast - An anastrozole adjuvant
trial was conducted in
9366 postmenopausal women with operable cancers of the breast
who were randomized to obtain adjuvant treatment with either anastrozole 1/>mg daily, NOLVADEX (tamoxifen citrate) 20 mg daily, or perhaps a mix of these two treatments for
several years or
until recurrence from the disease. For a median follow-up of 33 months,
the amalgamation of anastrozole and NOLVADEX (tamoxifen citrate)
did not demonstrate any efficacy
benefit in comparison to NOLVADEX (tamoxifen citrate) therapy alone in most patients together with
in
the hormone receptor-positive subpopulation. This procedure arm was discontinued
on the trial. Please consider CLINICAL PHARMACOLOGY-Special Populations-Drug-Drug
Interactions, PRECAUTIONS-Laboratory Tests,
PRECAUTIONS-Drug Interactions
and ADVERSE REACTIONS sections for safety information from this trial. Please talk about the entire prescribing information for
ARIMIDEX (anastrozole)
1 mg Tablets for more information about this trial.
Patients inside two monotherapy arms with the ATAC
trial were treated to get a median
of 60 months (Five years) and followed for a median of 68 months.
Disease-free
survival from the intent-to-treat population was statistically significantly improved
[Hazard Ratio (HR) = 0. 87, 95% CI: 0. 78,
0. 97, p=0. 0127] from the anastrazole
arm in comparison to the NOLVADEX (tamoxifen citrate) arm.
Node Positive -
Individual Studies
Two studies (Hubay and NSABP B-09) demonstrated a better disease-free survival
following radical or modified radical mastectomy in
postmenopausal women or
women Half a century of age or older with surgically curable breast cancer with positive
axillary nodes
when NOLVADEX (tamoxifen citrate) was combined with adjuvant cytotoxic chemotherapy. In
the Hubay study, NOLVADEX (tamoxifen citrate) was combined with
&lequo;low-dose"CMF (cyclophosphamide, methotrexate
and fluorouracil). Within the NSABP B-09 study, NOLVADEX (tamoxifen citrate) was included in melphalan
[L-phenylalanine mustard (P)]
and fluorouracil (F).
In the Hubay study, patients with a positive (over 3 fmol) estrogen receptor
were almost certainly
going to benefit. Inside the NSABP B-09 study girls age 50-59 years,
only women with both estrogen and progesterone receptor
levels 10 fmol or greater
clearly benefited, while there was clearly a nonstatistically significant trend toward
adverse effect in females
with both estrogen and progesterone receptor levels
below 10 fmol. Girls age 60-70 years, there is a trend toward the
perfect
effect of NOLVADEX (tamoxifen citrate) without any clear relationship to estrogen or progesterone
receptor status.
Three prospective studies
(ECOG-1178, Toronto, NATO) using NOLVADEX (tamoxifen citrate) adjuvantly
to be a single agent demonstrated an increased disease-free survival following total/>mastectomy and axillary dissection for postmenopausal women with positive axillary
nodes in comparison with placebo/no treatment controls. The NATO study
also demonstrated
a comprehensive survival benefit.
Node Negative - Individual Studies
NSABP B-14, a prospective, double-blind, randomized study, compared
NOLVADEX (tamoxifen citrate)
to placebo girls with axillary node-negative, estrogen-receptor positive
( ≥ 10 fmol/mg cytosol protein) breast cancers (as
adjuvant therapy, following
total mastectomy and axillary dissection, or segmental resection<, axillary dissection,
and breast radiation). After five years of
treatment, there was a significant
improvement in disease-free survival in women receiving NOLVADEX (tamoxifen citrate) . This benefit
was apparent
both in women under age 50 and in women at or beyond age 50.
One additional randomized study (NATO)
demonstrated improved disease-free survival
for NOLVADEX (tamoxifen citrate) compared to no adjuvant therapy following total mastectomy and
axillary dissection in
postmenopausal women with axillary node-negative breast
cancer. In this particular study, the advantages of NOLVADEX (tamoxifen citrate) appeared being separate
from
estrogen receptor status.
Duration of Therapy
In the EBCTCG 1995 overview, the lowering of recurrence and mortality was/>greater in those studies that used tamoxifen for approximately A few years compared to those
that used tamoxifen to get
a shorter period of therapy.
In the NSABP B-14 trial, in which patients were randomized to NOLVADEX (tamoxifen citrate)
20 mg/day
for 5 years vs. placebo and were disease-free at the end of this 5-year period
were offered rerandomization
to an additional A few years of NOLVADEX (tamoxifen citrate) or placebo. With Four years of follow-up next rerandomization, 92%
on the women that
received 5 years of NOLVADEX (tamoxifen citrate) were alive and disease-free, in comparison with 86% of/>the girls scheduled to take delivery of Ten years of NOLVADEX (tamoxifen citrate) (p=0. 003). Overall survivals
were 96% and
94%, respectively (p=0. 08). Link between the B-14 study advise that
continuation of therapy beyond Five years does not provide
additional benefit.
A Scottish trial of Five years of tamoxifen vs. indefinite treatment found a disease-free
survival of 70%
inside five-year group and 61% from the indefinite group, with
6. Couple of years median follow-up (HR=1. 27, 95% CI
0. 87-1. 85).
In a substantial randomized trial conducted through the Swedish Breast Cancer Cooperative
Group of adjuvant NOLVADEX
(tamoxifen citrate) 40 mg/day for two or 5 years, overall survival at 10
years was estimated for being 80% from
the patients from the 5-year tamoxifen group,
in contrast to 74% among corresponding patients from the 2-year treatment group
(p=0.
03). Disease-free survival at Several years was 73% within the 5-year group and
67% from the 2-year group (p=0. 009).
Compared with Couple of years of tamoxifen treatment,
5 years of treatment ended in a rather greater decline in the
incidence
of contralateral breast cancers at Ten years, but this difference hasn't been statistically
significant.
Contralateral Breast cancers
The
incidence of contralateral cancers of the breast is reduced in breast cancer patients
(premenopausal and postmenopausal) receiving NOLVADEX (tamoxifen citrate)
compared to placebo. Data
on contralateral cancer of the breast can be found from 32,422 away from 36,689 patients
inside
the 1995 overview research into the Early Cancers of the breast Trialists Collaborative
Group (EBCTCG). In many studies with NOLVADEX
(tamoxifen citrate) of 12 months or less, A couple of years,
resulting in 5yrs duration, the proportional reductions inside the
incidence rate
of contralateral cancer of the breast among women receiving NOLVADEX (tamoxifen citrate) were 13% (NS),
26% (2p =
0. 004) and 47% (2p < 0. 00001), with a significant trend favoring
longer tamoxifen duration (2p = 0. 008).
The proportional reductions in the incidence
of contralateral breast cancer were independent of age and ER status of the
primary
tumor. Treatment with about 5 years of NOLVADEX (tamoxifen citrate) reduced the annual incidence
rate of contralateral breast cancer from
7. 6 per 1,000 patients in the control
group compared with 3. 9 per 1,000 patients in the tamoxifen group.
In a sizable randomized trial in Sweden (the Stockholm Trial) of adjuvant NOLVADEX (tamoxifen citrate)
40 mg/day for 2-5
years, the incidence of second primary breast tumors was reduced
40% (p < 0. 008) on tamoxifen compared to control.
In the NSABP B-14 trial
in which patients were randomized to NOLVADEX (tamoxifen citrate) 20 mg/day for 5 years vs.
placebo,
the incidence of second primary breast cancers was also significantly reduced
(p < 0. 01). In NSABP B-14, the
annual rate of contralateral breast cancer
was 8. 0 per 1000 patients in the placebo group compared with 5. 0
per 1,000 patients
in the tamoxifen group, at 10 years after first randomization.
Ductal Carcinoma in Situ
NSABP B-24,
a double-blind, randomized trial included women with ductal carcinoma in situ (DCIS). This trial compared the addition of NOLVADEX (tamoxifen
citrate) or placebo to treatment
with lumpectomy and radiation therapy for girls with DCIS. The primary objective
would have been
to evaluate if 5 years of NOLVADEX (tamoxifen citrate) therapy (20 mg/day) would reduce
the incidence of invasive cancer of
the breast inside ipsilateral (precisely the same) or contralateral
(the exact opposite) breast.
In this trial 1,804 women were
randomized to obtain either NOLVADEX (tamoxifen citrate) or placebo
for 5 years: 902 women were randomized to NOLVADEX (tamoxifen citrate)
10 mg tablets two times a day
and 902 women were randomized to placebo. Since December 31, 1998, follow-up
data
were available for 1,798 women and the median use of follow-up was
74 months.
The NOLVADEX (tamoxifen citrate) and
placebo groups were well-balanced for baseline demographic
and prognostic factors. Over 80% with the tumors were under or equal to
1
cm within their maximum dimension, just weren't palpable, and were detected by mammography
alone. Over 60% of the study
population was postmenopausal. In 16% of patients,
the margin with the resected specimen was reported as being positive after surgery.
Approximately one half of the tumors were reported to contain comedo necrosis.
For the main endpoint, the incidence of
invasive breast cancers was reduced
by 43% among women assigned to NOLVADEX (tamoxifen citrate) (44 cases - NOLVADEX (tamoxifen citrate)
, 74 cases - placebo;
p=0. 004; relative risk (RR)=0. 57, 95% CI: 0. 39-0. 84). No data can be
purchased
regarding the ER status in the invasive cancers. Activity is distribution with the
invasive cancers at diagnosis was similar
to that reported annually inside the SEER
data base.
Results are shown in Table 1. For every endpoint the
subsequent results are presented:
the volume of events and rate per 1,000 women annually with the placebo and NOLVADEX (tamoxifen
citrate)
groups; and the relative risk (RR) as well as associated 95% confidence interval
(CI) between NOLVADEX (tamoxifen citrate) and
placebo. Relative risks under 1. 0 indicate a benefit
of NOLVADEX (tamoxifen citrate) therapy. The limits with the confidence intervals
enables you to assess
the statistical significance on the important things about NOLVADEX (tamoxifen citrate) therapy. In the event the
upper
limit in the CI is lower than 1. 0, then a statistically significant benefit exists.
Table 1.
Major Eating habits study the NSABP B-24 Trial
Sort of Event
Lumpectomy, radiotherapy, and placebo
Lumpectomy, radiotherapy, andNOLVADEX
RR
95% CI Limits
No. of events
Rate per 1000 women a year
No. of events
Rate per 1000
women annually
Invasive cancer of the breast (Primary endpoint)
74
16. 73
44
9. 60
0. 57
0. 39 to
0. 84
-Ipsilateral
47
10. 61
27
5. 90
0. 56
0. 33 to 0. 91
-Contralateral
25
5. 64/>17
3. 71
0. 66
0. 33 to at least one. 27
-Side undertermined
2
--
0
--
--
Secondary
Endpoints
DCIS
56
12. 66
41
8. 95
0. 71
0. 46 to 1. 08
-Ipsilateral
46
10. 40
38/>8. 29
0. 88
0. 51 to at least one. 25
-Contralateral
10
2. 26
3
0. 65
0. 29/>0. 05 to at least one. 13
All Cancer of the breast Events
129
29. 16
84
18. 34
0.
63
0. 47 to 0. 83
-All ipsilateral events
96
21. 70
65
14. 19
0. 65
0. 47 to
0. 91
-All contralateral events
37
8. 36
20
4. 37
0. 52
0. 29 to 0. 92
Deaths
32/>28
Uterine Malignancies1
4
9
Endometrial Adenocarcinoma1
4
0. 57
8
1. 15
Uterine Sarcoma1
0
0. 0
1
0.
14
Second primary malignancies (in addition to endometrial and breast)
30
29
Stroke
2
7
Thromboembolic events (DVT, PE)
5/>15
1Updated follow-up data (median
8. 1 years)
Survival was similar inside the placebo and NOLVADEX (tamoxifen citrate) groups.
At 5 years from study
entry, survival was 97% for groups.
Reduction in Cancers of the breast Incidence in
High-risk Women:
The Cancer of the breast Prevention Trial (BCPT, NSABP P-1) would have been a double-blind, randomized,
placebo-controlled trial
that has a primary objective to discover whether 5yrs
of NOLVADEX (tamoxifen citrate) therapy (20 mg/day) would slow up the
incidence of invasive breast
cancer ladies at riskly for that disease (See INDICATIONS AND USAGE). Secondary objectives included the test
on the incidence of ischemic heart
disease; the end results around the incidence of bone fractures; along with events that/>may very well be of this particular use of NOLVADEX (tamoxifen citrate) , including: endometrial cancer,
pulmonary embolus, deep vein
thrombosis, stroke, and cataract formation and
surgery (See WARNINGS).
The Gail Model was implemented to calculate predicted breast cancers
risk for ladies
who had been less than Six decades of aging and didn't have lobular carcinoma in situ
(LCIS).
These risk factors were put to use: age; volume of first-degree female
relatives with cancers of the breast; previous breast
biopsies; presence or absence
of atypical hyperplasia; nulliparity; age in the beginning live birth; and age at menarche. A 5-year
predicted probability of cancers of the breast of ≥ 1. 67% was essential for entry
in to the trial.
/>
In this trial, 13,388 women that is at least 35 years of age were randomized to
receive either NOLVADEX (tamoxifen
citrate) or placebo for 5yrs. The median length of treatment
was 3. 5yrs. By January 31, 1998, follow-up results are
intended for 13,114
women. Twenty-seven percent of ladies randomized to placebo (1,782) and 24% of
women randomized to NOLVADEX (tamoxifen
citrate) (1,596) completed Several years of therapy. The demographic
characteristics of females about the trial with follow-up data are shown
in Table
2.
Table 2. Demographic Characteristics of ladies in the NSABP
P-1 Trial
Characteristic
Placebo
Tamoxifen
#
%
#
%
Age (yrs. )
35-39
184
3
158
2
40-49
2,394
36
2,411
37
50-59
2,011/>31
2,019
31
60-69
1,588
24
1,563
24
≥ 70
393
6
393
6
Age initially live birth (yrs. )/>Nulliparous
1,202
18
1,205
18
12-19
915
14
946
15
20-24
2,448
37
2,449
37
25-29
1,399
21
1,367
21/>≥ 30
606
9
577
9
Race
White
6,333
96
6,323
96
Black
109
2
103
2
Other
128
2/>118
2
Age at menarche
≥ 14
1,243
19
1,170
18
12-13
3,610
55
3,610
55
≤ 11
1,717
26/>1,764
27
# of first degree relatives with cancer of the breast
0
1,584
24
1,525
23
1
3,714
57/>3,744
57
2+
1,272
19
1,275
20
Prior Hysterectomy
No
4,173
63. 5
4,018
62. 4
Yes
2,397
36. 5/>2,464
37. 7
# of previous breast biopsies
0
2,935
45
2,923
45
1
1,833
28
1,850
28
≥ 2/>1,802
27
1,771
27
Good atypical hyperplasia in the breast
No
5,958
91
5,969
91
Yes
612
9
575
9/>History of LCIS at entry
No
6,165
94
6,135
94
Yes
405
6
409
6
5-year predicted breast cancers risk
(%)
≤ 2. 00
1,646
25
1,626
25
2. 01-3. 00
2,028
31
2,057
31
3. 01-5. 00
1,787
27/>1,707
26
≥ 5. 01
1,109
17
1,162
18
Total
6,570
100. 0
6,544
100. 0
Results are shown
in Table 3. From a median follow-up of 4. Couple of years, the incidence
of invasive breast cancers was reduced
by 44% among women used on NOLVADEX (tamoxifen citrate)
(86 cases-NOLVADEX (tamoxifen citrate) , 156 cases-placebo; p < 0. 00001;
relative risk (RR)=0. 56,
95% CI: 0. 43-0. 72). A reduction in the incidence of breast cancer was seen in/>each prospectively specified age group ( ≤ 49, 50-59, ≥ 60), in women with
or without LCIS, and in each
of the absolute risk levels specified in Table
3. A non-significant decrease in the incidence of ductal carcinoma in situ
(DCIS)
was seen (23-NOLVADEX (tamoxifen citrate) , 35-placebo; RR=0. 66; 95% CI: 0. 39-1. 11).
There wasn't any statistically
factor within the volume of myocardial
infarctions, severe angina, or acute ischemic cardiac events between your two
groups (61-NOLVADEX (tamoxifen
citrate) , 59-placebo; RR=1. 04, 95% CI: 0. 73-1. 49).
No overall difference in mortality (53 deaths in NOLVADEX
(tamoxifen citrate) group vs. 65 deaths
in placebo group) was present. No difference in breast cancer-related mortality
was observed (4
deaths in NOLVADEX (tamoxifen citrate) group vs. 5 deaths in placebo group).
Although there is a non-significant reduction in
how many hip fractures
(9 on NOLVADEX (tamoxifen citrate) , 20 on placebo) in the NOLVADEX (tamoxifen citrate) group, the
quantity of wrist fractures
was similar inside the two treatment groups (69 on NOLVADEX (tamoxifen citrate) , 74 on placebo).
A subgroup
research into the P-1 trial, suggests an improvement essentially in bone mineral density
(BMD) associated with menopausal status
in patients receiving NOLVADEX (tamoxifen citrate) . In postmenopausal
women there was clearly no proof of bone loss of the
lumbar spine and hip. Conversely,
NOLVADEX (tamoxifen citrate) was associated with significant bone decrease of the lumbar spine and hip/>in premenopausal women.
The risks of NOLVADEX (tamoxifen citrate) therapy include endometrial cancer, DVT, PE, stroke,
cataract formation and
cataract surgery (See Table 3). Inside the NSABP P-1 trial,
33 cases of endometrial cancer were seen in the NOLVADEX
(tamoxifen citrate) group vs. 14 in
the placebo group (RR=2. 48, 95% CI: 1. 27-4. 92). Deep vein thrombosis was
observed
in 30 women receiving NOLVADEX (tamoxifen citrate) vs. 19 girls receiving placebo (RR=1. 59, 95%
CI: 0. 86-2. 98).
Eighteen cases of pulmonary embolism were affecting the NOLVADEX (tamoxifen citrate)
group vs. 6 within the placebo group (RR=3. 01,
95% CI: 1. 15-9. 27). There were 34
strokes on the NOLVADEX (tamoxifen citrate) arm and 24 within the placebo
arm (RR=1. 42; 95% CI: 0. 82-2. 51). Cataract formation in ladies without cataracts at baseline was seen in 540/>women taking NOLVADEX (tamoxifen citrate) vs. 483 women receiving placebo (RR=1. 13, 95% CI: 1. 00-1. 28). Cataract surgery (with
or without cataracts at baseline) was performed in 201
women taking NOLVADEX (tamoxifen citrate) vs. 129 women receiving placebo (RR=1.
51, 95% CI: 1. 21-1. 89)
(See WARNINGS).
Table 3 summarizes the major eating habits study the NSABP P-1
trial. Per endpoint,
the next answers are presented: how many events and rate per 1000
women per annum for the
placebo and NOLVADEX (tamoxifen citrate) groups; plus the relative risk (RR)
and its particular associated 95% confidence interval (CI) between
NOLVADEX (tamoxifen citrate) and placebo. Relative risks below 1. 0 indicate an improvement of NOLVADEX (tamoxifen citrate) therapy. The limits/>from the confidence intervals may be used to appraise the statistical significance
on the benefits or hazards of NOLVADEX (tamoxifen
citrate) therapy. If your upper limit from the CI is
lower than 1. 0, after that statistically significant benefit exists.
For most participants, multiple risk factors could have been needed for eligibility. This table considers risk factors individually, irrespective
of other co-existing
risk factors, for girls who developed breast cancers. The 5-year predicted absolute
cancer of the breast risk
accounts for multiple risks inside an individual and will
supply the best estimate of individual benefit (See INDICATIONS AND USAGE).
Table 3. Major Outcomes of the NSABP P-1 Trial
# OF EVENTS
RATE/1000 WOMEN/YEAR
95% CI
Kind of EVENT
PLACEBO
NOLVADEX
PLACEBO
NOLVADEX
RR
LIMITS
Invasive Cancers of the breast
156
86
6. 49
3. 58/>0. 56
0. 43-0. 72
Age ≤ 49
59
38
6. 34
4. 11
0. 65
0. 43-0. 98
Age
50-59
46
25
6. 31
3. 53
0. 56
0. 35-0. 91
Age ≥ 60
51
23
7. 17
3.
22
0. 45
0. 27-0. 74
Risks for Cancer of the breast History, LCIS
No
140
78
6. 23
3.
51
0. 56
0. 43-0. 74
Yes
16
8
12. 73
6. 33
0. 50
0. 21-1. 17
History, Atypical
Hyperplasia
No
138
84
6. 37
3. 89
0. 61
0. 47-0. 80
Yes
18
2
8. 69
1. 05/>0. 12
0. 03-0. 52
No. First Degree Relatives
0
32
17
5. 97
3. 26
0. 55
0. 30-0.
98
1
80
45
5. 81
3. 31
0. 57
0. 40-0. 82
2
35
18
8. 92
4. 67/>0. 52
0. 30-0. 92
≥ 3
9
6
13. 33
7. 58
0. 57
0. 20-1. 59
5-Year Predicted
Breast cancers Risk (as calculated by
the Gail Model)
≤ 2. 00%
31
13
5. 36
2. 26
0. 42/>0. 22-0. 81
2. 01-3. 00%
39
28
5. 25
3. 83
0. 73
0. 45-1. 18
3. 01-5. 00%/>36
26
5. 37
4. 06
0. 76
0. 46-1. 26
≥ 5. 00%
50
19
13. 15
4. 71/>0. 36
0. 21-0. 61
DCIS
35
23
1. 47
0. 97
0. 66
0. 39-1. 11
Fractures (protocol-specified sites)/>921
761
3. 87
3. 20
0. 61
0. 83-1. 12
Hip
20
9
0. 84
0. 38
0. 45/>0. 18-1. 04
Wrist2
74
69
3. 11
2. 91
0. 93
0. 67-1. 29
Total Ischemic Events
59
61/>2. 47
2. 57
1. 04
0. 71-1. 51
Myocardial Infarction
27
27
1. 13
1. 13
1. 00
0.
57-1. 78
Fatal
8
7
0. 33
0. 29
0. 88
0. 27-2. 77
Nonfatal
19
20
0. 79
0.
84
1. 06
0. 54-2. 09
Angina3
12
12
0. 50
0. 50
1. 00
0. 41-2. 44
Acute Ischemic
Syndrome4
20
22
0. 84
0. 92
1. 11
0. 58-2. 13
Uterine Malignancies (among women with the intact uterus)10/>17
57
Endometrial Adenocarcinoma10
17
53
0. 71
2. 20
Uterine Sarcoma10
0
4
0. 0
0. 17
Stroke5
24/>34
1. 00
1. 43
1. 42
0. 82-2. 51
Transient Ischemic Attack
21
18
0. 88
0. 75
0.
86
0. 43-1. 70
Pulmonary Emboli6
6
18
0. 25
0. 75
3. 01
1. 15-9. 27
Deep-Vein Thrombosis7
19/>30
0. 79
1. 26
1. 59
0. 86-2. 98
Cataracts Developing on Study8
483
540
22. 51
25. 41/>1. 13
1. 00-1. 28
Underwent Cataract Surgery8
63
101
2. 83
4. 57
1. 62
1. 18-2. 22
Underwent
Cataract Surgery9
129
201
5. 44
8. 56
1. 58
1. 26-1. 97
1Two women had hip and wrist fractures/>
2 Includes Colles' and other lower radiusfractures
3Requiring angioplasty or CABG
4New Q-wave on ECG; noangina or elevation of serum enzymes;
or angina requiring hospitalization without surgery
5Seven cases were fatal; three withinthe placebo group and four
within the NOLVADEX (tamoxifen citrate) group
6Three cases inside the NOLVADEX (tamoxifen citrate)group were fatal
7All but three cases in each group required hospitalization
8Based on women withoutcataracts at baseline (6,230-Placebo,
6,199-NOLVADEX (tamoxifen citrate) )
9All women (6,707-Placebo, 6,681-NOLVADEX (tamoxifen citrate) )
10Updatedlong-term follow-up data (median 6. 9 years) from
NSABP P-1 study added after cut-off for your other information with this/>table.
Table 4 describes the characteristics on the breast cancers from the NSABP P-1
trial and includes tumor size,
nodal status, ER status. NOLVADEX (tamoxifen citrate) decreased the
incidence of small estrogen receptor positive tumors, but failed to customize
the
incidence of estrogen receptor negative tumors or larger tumors.
Table 4. Characteristics of Cancers of the breast
in NSABP P-1 Trial
Staging Parameter
Placebo
N=156
Tamoxifen
N=86
Total
N=242
Tumor Size:
T1/>117
60
177
T2
28
20
48
T3
7
3
10
T4
1
2
3
Unknown
3
1
4
Nodal
status:
Negative
103
56
159
1-3 positive nodes
29
14
43
≥ 4 positive nodes
10
12
22
Unknown
14/>4
18
Stage:
I
88
47
135
II: node negative
15
9
24
II: node positive
33
22
55
III/>6
4
10
IV
21
1
3
Unknown
12
3
15
Estrogen receptor:
Positive
115
38
153
Negative
27
36/>63
Unknown
14
12
26
1One participant shown
a suspicious bone scan but was without documented metastases. She subsequently
died
of metastatic breast cancer.
Interim comes from 2 trials beyond the NSABP P-1 trial examining
the results of tamoxifen
in reducing breast cancer incidence happen to be reported.
The first was an italian man , Tamoxifen Prevention trial.
Within this trial women between
time of 35 and 70, who had had a total hysterectomy, were randomized to
receive
20 mg tamoxifen or matching placebo for 5 years. The principal endpoints
were occurrence of, and death from, invasive cancers
of the breast. Women with virtually no
specific risks for breast cancers may be entered. Between 1992 and
1997, 5408
women were randomized. Hormone Replacement Therapy (HRT) was implemented
in 14% of participants. The trial closed in 1997 a result
of the large number of
dropouts through the fresh of treatment (26%). After 46 months of follow-up
there was 22
breast cancers in ladies on placebo and 19 in females on tamoxifen. Although no decrease in breast cancer incidence was
observed, there were a trend
to get a reduction in cancers of the breast among women receiving protocol therapy for/>at the least One year (19-placebo, 11- tamoxifen). The small variety of participants
together with the low-level of risk within
this otherwise healthy group precluded an
adequate assessment with the effect of tamoxifen in cutting the incidence of
cancers of
the breast.
The second trial, the Royal Marsden Trial (RMT) was reported as an interim
analysis. The RMT was
begun in 1986 to be a feasibility study of whether larger
scale trials might be mounted. The trial was subsequently
extended to a pilot
trial to accrue additional participants to help expand look at the safety of tamoxifen. Twenty-four hundred
and seventy-one women were entered between 1986 and 1996;
these folks were selected on such basis as children good reputation
for cancer of the breast. HRT was
employed in 40% of participants. With this trial, which has a 70 month
median follow-up,
34 and 36 breast cancers (8 noninvasive, 4 on each arm) were observed among
women on tamoxifen and
placebo, respectively. Patients in this particular trial were a kid
than those from the NSABP P-1 trial and may even
are already more likely to develop ER
(-) tumors, that happen to be unlikely for being reduced in number by
tamoxifen therapy. Although women were selected by genealogy and family history and were thought
to get a high-risk of cancer
of the breast, few events occurred, decreasing the statistical
power in the study. These factors are potential main reasons why
the RMT may not
have provided an adequate assessment from the effectiveness of tamoxifen in lessening
the incidence of cancer
of the breast.
In these trials, a greater number of instances of deep vein thrombosis, pulmonary
embolus, stroke, and
endometrial cancer were observed within the tamoxifen arm compared
to your placebo arm. The regularity of events was like safety
data
noticed in the NSABP P-1 trial.
McCune-Albright Syndrome
A single, uncontrolled multicenter trial of NOLVADEX (tamoxifen citrate) 20
mg every day was conducted
in the heterogenous list of girls with McCune-Albright Syndrome and precocious puberty manifested by physical
warning signs of pubertal development, instances of vaginal
bleeding and/or advanced bone age (bone ages of at the least Twelve
months beyond chronological
age). Twenty-eight female pediatric patients, aged 2 to 10 years, were treated
for approximately 1 year. Effect
of treatment on frequency of vaginal bleeding, bone
age advancement, and linear rate of growth was assessed in accordance with
prestudy baseline. NOLVADEX (tamoxifen citrate) treatment was of the 50% cut in frequency of vaginal
bleeding episodes by patient or
family report (mean annualized frequency of
3. 56 episodes at baseline and 1. 73 episodes on-treatment). One of several patients/>who reported vaginal bleeding throughout the pre-study period, 62% (13 from 21
patients) reported no bleeding for any 6-month period
and 33% (7 beyond 21 patients)
reported no vaginal bleeding all through the trial. Its not all patients
improved on
treatment and a few patients not reporting vaginal bleeding from the
A few months previous to enrollment reported menses on
treatment. NOLVADEX (tamoxifen citrate) therapy
was from a decrease in mean rate of increase of bone age. Individual
responses regarding
bone age advancement were highly heterogeneous. Linear
rate of growth was reduced during the course of NOLVADEX (tamoxifen citrate) treatment
in the majority
of patients (mean change of 1. 68 cm/year compared to baseline; differ from 7. 47
cm/year at
baseline to five. 79 cm/year on study). This alteration wasn't uniformly
seen across all stages of bone maturity; all recorded
response failures occurred
in patients with bone ages less than 7 years at screening.
Mean uterine volume increased after
Half a year of treatment and doubled on the
end of the one-year study. A causal relationship has not been
established; however,
as an surge in the incidence of endometrial adenocarcinoma and uterine sarcoma
continues to be noted in older
adults treated with NOLVADEX (see BOXED
WARNING), continued monitoring of McCune-Albright patients addressed with
NOLVADEX (tamoxifen citrate) for long-term uterine
effects is recommended. The protection and efficacy
of NOLVADEX (tamoxifen citrate) for girls aged two to 10 years with McCune-Albright
Syndrome and
precocious puberty were not studied beyond twelve months of treatment buy celebrex online no prescription. The long-term/>connection between NOLVADEX (tamoxifen citrate) therapy in girls are not established.
Last reviewed on RxList: 4/10/2008
This monograph has
become modified to include the generic and name in many instances.
.
RSS feed